Related Experiment Video
Updated: Mar 31, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Intellectual property issues of immune checkpoint inhibitors
1a Senior Partner, Michalski; Hüttermann Patent Attorneys ; Düsseldorf , Germany.
Abstract:
Immune checkpoint inhibitors are drugs that interfere with tumor escape responses. Some members of this class are already approved, and expected to be blockbusters in the future. Many companies have developed patent activities in this field. This article focuses on the patent landscape, and discusses key players and cases related to immune checkpoint inhibitors.
Related Concept Videos
Tumor Immunotherapy
Immunoprecipitation
Chromatin Immunoprecipitation
Chromatin immunoprecipitation, also known as ChIP, is used to study protein-DNA or...
Drug Products: Biologics, Biosimilars and Interchangeables
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Inhibition of Cdk Activity
Inhibitors of Viral Protein Synthesis

